TABLE 1.
Patient Characteristics |
SBA Stage I N=468 |
LBA Stage I N=51,221 |
SBA Stage II N=1,360 |
LBA Stage II N=87,085 |
SBA Stage III N=1,238 |
LBA Stage III N=71,726 |
SBA Stage IV N=1,452 |
LBA Stage IV N=51,489 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | N | % | N | % | N | % | N | % | N | % | ||
Age | P <.01 | P <.01 | P <.01 | P <.01 | |||||||||||||
<50 years | 51 | 11 | 2,667 | 5 | 199 | 15 | 5,491 | 6 | 201 | 16 | 6,418 | 9 | 181 | 12 | 5,537 | 11 | |
50–75 years | 245 | 52 | 27,534 | 54 | 757 | 56 | 41,808 | 48 | 700 | 57 | 38,001 | 53 | 843 | 58 | 29,023 | 56 | |
>75 years | 172 | 37 | 21,020 | 41 | 404 | 30 | 39,786 | 46 | 337 | 27 | 27,307 | 38 | 428 | 29 | 16,929 | 33 | |
Year of diagnosis | P =0.01 | P <.01 | P =0.01 | P <.01 | |||||||||||||
1988–1992 | 46 | 10 | 6,288 | 12 | 151 | 11 | 13,328 | 15 | 132 | 11 | 9,498 | 13 | 170 | 12 | 7,417 | 14 | |
1993–1997 | 64 | 14 | 8,157 | 16 | 223 | 16 | 16,719 | 19 | 217 | 18 | 13,088 | 18 | 235 | 16 | 9,529 | 19 | |
1998–2002 | 135 | 29 | 16,148 | 32 | 412 | 30 | 27,182 | 31 | 384 | 31 | 22,571 | 31 | 437 | 30 | 15,360 | 30 | |
2003–2007 | 223 | 48 | 20,628 | 40 | 574 | 42 | 29,856 | 34 | 505 | 41 | 26,569 | 37 | 610 | 42 | 19,183 | 37 | |
Gender | P =0.16 | P <.01 | P <.01 | P <.01 | |||||||||||||
Male | 249 | 53 | 25,616 | 50 | 697 | 51 | 41,378 | 48 | 676 | 55 | 34,293 | 48 | 796 | 55 | 25,930 | 50 | |
Female | 219 | 47 | 25,605 | 50 | 663 | 49 | 45,707 | 52 | 562 | 45 | 37,433 | 52 | 656 | 45 | 25,559 | 50 | |
Race | P <.01 | P <.01 | P <.01 | P <.01 | |||||||||||||
White | 359 | 77 | 43,390 | 85 | 1,062 | 78 | 73,459 | 84 | 994 | 80 | 58,309 | 81 | 1,107 | 76 | 41,101 | 80 | |
Black | 77 | 16 | 4,383 | 9 | 215 | 16 | 7,600 | 9 | 168 | 14 | 7,390 | 10 | 253 | 17 | 6,767 | 13 | |
Other | 32 | 7 | 3,448 | 7 | 83 | 6 | 6,026 | 7 | 76 | 6 | 6,027 | 8 | 92 | 6 | 3,621 | 7 | |
Tumor Grade | P <.01 | P <.01 | P <.01 | P <.01 | |||||||||||||
Well-Moderate | 280 | 60 | 42,406 | 83 | 887 | 65 | 68,923 | 79 | 635 | 51 | 49,129 | 68 | 590 | 41 | 29,212 | 57 | |
Poor | 86 | 18 | 4,267 | 8 | 382 | 28 | 15,289 | 18 | 508 | 41 | 20,159 | 28 | 514 | 35 | 14,484 | 28 | |
Unknown | 102 | 22 | 4,548 | 9 | 91 | 7 | 2,873 | 3 | 95 | 8 | 2,438 | 3 | 348 | 24 | 7,793 | 15 | |
Site | |||||||||||||||||
Duodenum | 320 | 68 | 591 | 43 | 691 | 56 | 773 | 53 | |||||||||
Jejunum | 52 | 11 | 316 | 23 | 242 | 20 | 256 | 18 | |||||||||
Ileum | 67 | 14 | 234 | 17 | 184 | 15 | 170 | 12 | |||||||||
Small bowel NOS | 29 | 6 | 219 | 16 | 121 | 10 | 253 | 17 | |||||||||
Total LN assessed | P <.01 | P <.01 | P <.01 | ||||||||||||||
Median (IQR) | 0 (0–6) | 9 (5–15) | 4 (0–10) | 12 (7–18) | 8 (3–13) | 12 (8–18) | |||||||||||
Positive LN | - | - | P <.01 | ||||||||||||||
Median (IQR) | 0 | 0 | 0 | 0 | 2(1–4) | 2(1–4) |
Abbreviations: SBA, small bowel adenocarcinoma; LBA, large bowel adenocarcinoma; NOS, not otherwise specified; LN, lymph node; IQR, interquartile range.